about the author

Amber Tong

amber@endpointsnews.com @AmberTongPW
Amber Tong on LinkedIn

author articles

Three months af­ter big re­or­ga­ni­za­tion, an­ti­body mak­er Atre­ca is back with an­oth­er round of lay­offs

Last year
People

As­traZeneca leans in­to GLP-1; Cuts loom­ing at Bay­er; Eli Lil­ly’s obe­si­ty ap­proval; End­points Slack in­ter­view with ...

Last year
Weekly

Take­da scores FDA ap­proval for $400M col­orec­tal can­cer ther­a­py

Last year
Pharma
FDA+

As­traZeneca spot­lights bis­pecifics in can­cer as it rais­es guid­ance, while prun­ing rare dis­ease pipeline

Last year
R&D
Pharma

As­traZeneca puts down $185M up­front for PhI oral GLP-1 as it shoots for next-gen win

Last year
Deals
R&D

No­var­tis slots PhI car­dio­vas­cu­lar can­di­date in­to pipeline, pay­ing Ko­re­an part­ner $80M up­front

Last year
Deals
R&D

BioN­Tech grabs PD-L1/VEGF bis­pe­cif­ic with $55M up­front, ex­pand­ing pipeline while low­er­ing Covid guid­ance

Last year
Deals
China

RAPT Ther­a­peu­tics bol­sters part­ner search with PhII da­ta on small mol­e­cule-Keytru­da com­bo

Last year
R&D

Lat­est news on BioN­Tech's Fri­day buy­out; Un­pack­ing Sarep­ta’s Duchenne da­ta; Pfiz­er’s post-Covid plans; Eli Lil­ly, ...

Last year
Weekly

No­vo Nordisk tem­pers ex­pec­ta­tions for hefty M&A deals as di­a­betes, obe­si­ty sales soar

Last year
Pharma

Sang­amo lays off 160+ staffers, winds down fa­cil­i­ty, punts clin­i­cal pro­grams in dras­tic re­vamp

Last year
People
R&D

Kite en­lists Epic Bio to ap­ply epi­ge­net­ic edit­ing in cre­at­ing next-gen CAR-T cells

Last year
Deals
Cell/Gene Tx

FDA green­lights first made-in-Chi­na PD-1 as Jun­shi, Co­herus beat BeiGene to the punch

Last year
China
FDA+

Roche's $7.1B bet on Roivant drug; AD­Cs and oth­er #ES­MO23 dis­patch; High­lights from Alzheimer's con­fab; Q3 phar­ma ...

Last year
Weekly

How Bris­tol My­er­s' buy­out of­fer for Mi­rati dwin­dled by bil­lions of dol­lars

Last year
Deals

Up­dat­ed: No­var­tis 'on track' to com­plete re­struc­tur­ing post San­doz spin, push­es back Plu­vic­to fil­ing

Last year
R&D
Pharma

Mer­ck­'s big ADC move; Lat­est from #ES­MO23; How Eli Lil­ly is think­ing about deals; AI-de­signed drugs face reck­on­ing in ...

Last year
Weekly

Mer­ck dou­bles down on AD­Cs with $4B up­front to Dai­ichi Sankyo, go­ing for ‘same in­ten­si­ty’ as megablock­buster ...

Last year
Deals

PureTech gives up on re­gain­ing con­trol of Gele­sis and its weight loss pill

Last year
Deals

BioN­Tech ex­pects up to $950M in Covid vac­cine write-offs af­ter Pfiz­er low­ers ex­pec­ta­tions

Last year
Financing
Coronavirus

BMS buys Mi­rati for $4.8B; Pfiz­er to slash cost; Q&A with Ver­tex CSO; Al­ny­lam's On­pat­tro set­back; and more

Last year
Weekly

Har­mo­ny Bio­sciences' Wak­ix fails PhI­II hy­per­som­nia study; Flori­da gene ther­a­py start­up down­sizes

Last year
News Briefing

Pfiz­er lands FDA ap­proval for $6.7B ul­cer­a­tive col­i­tis drug, tak­ing on an­ti­bod­ies as an oral al­ter­na­tive

Last year
R&D
Pharma

FDA lifts hold on Pep­Gen's my­oton­ic dy­s­tro­phy drug; Take­da teams with can­cer non­prof­it

Last year
News Briefing
First page Previous page 567891011 Next page Last page
A service from the Financial Times